Prime Medicine, Inc. (PRME)
$3.13-5.72%Close
BUYCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $565M
- Beta
- 2.38
- P/E (TTM)
- -2.85
- Short % float
- 54.28%
- Days to cover
- 8.4
- SI change
- -0.1%
- 1W
- -19.74%
- 1M
- -0.32%
- vs SPY 1W
- -19.60%
- vs SPY 1M
- -2.82%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-113.0%
REV YoY-
ROE-188.3%
EPS YoY-
ROA-75.4%
GROSS-1026
OP-4825
NET-4613
[VALUATION]
P/E TTM-2.85
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B13.93
P/FCF-
EV/EBITDA-3.49
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E282.54
ALTMAN Z-
CURR RATIO3.05
ND/EBITDA-
BETA2.38
Company news
FAQ
- What is LOPJLB’s current signal on PRME?
- LOPJLB’s latest quantitative signal on Prime Medicine, Inc. (PRME) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is PRME in?
- Prime Medicine, Inc. (PRME) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Prime Medicine, Inc. (PRME) do?
- Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor proteinâa hybrid composed of a Cas protein and a reverse transcriptase enzymeâwith a specialized pegRNA molecule. This pe…